[Perspectives of Individualized Treatment by Genome-Wide Analyses in Ovarian Cancer].
Genome-wide analyses have recently been reported for ovarian cancer. High-grade serous ovarian carcinoma(HGSOC) almost exclusively harbor TP53 mutations and prominent copy number aberrations. Approximately 20% of HGSOCs harbor BRCA mutations, in which case PARP inhibitors may be effective. HGSOCs are classified into 4 molecular subtypes with distinct histopathological features by transcriptional profiling. These subtypes differ in prognosis and drug sensitivity. Additionally, a whole-genome analysis for HGSOC has revealed various factors that can induce resistance to chemotherapy. On the other hand, ovarian clear cell carcinoma(OCCC), a chemoresistant subtype, develops through oxidative stress conditions in an endometriotic cyst. OCCC specific genes include HNF1B and its downstream genes and genes related to oxidative stress. HNF1B mediates resistance to oxidative stress and platinum in OCCC cells. In the future, development of new therapeutic strategies based on these OCCC specific features is expected.